WO2018112219A4 - Superkine - Google Patents

Superkine Download PDF

Info

Publication number
WO2018112219A4
WO2018112219A4 PCT/US2017/066449 US2017066449W WO2018112219A4 WO 2018112219 A4 WO2018112219 A4 WO 2018112219A4 US 2017066449 W US2017066449 W US 2017066449W WO 2018112219 A4 WO2018112219 A4 WO 2018112219A4
Authority
WO
WIPO (PCT)
Prior art keywords
affinity
molecule complex
complex
receptor
portions
Prior art date
Application number
PCT/US2017/066449
Other languages
English (en)
Other versions
WO2018112219A1 (fr
Inventor
Patrick Soon-Shiong
Original Assignee
Nant Holdings Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings Ip, Llc filed Critical Nant Holdings Ip, Llc
Publication of WO2018112219A1 publication Critical patent/WO2018112219A1/fr
Publication of WO2018112219A4 publication Critical patent/WO2018112219A4/fr
Priority to US16/442,265 priority Critical patent/US11053299B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés comprenant des complexes de molécules chimériques qui fournissent de manière avantageuse une signalisation d'activation à des cellules immunocompétentes lorsqu'elles sont liées à des cellules ALL. En outre, les complexes de molécules chimériques comprennent une partie Fc pour prolonger le temps de demi-vie du sérum et faciliter la purification.
PCT/US2017/066449 2010-09-21 2017-12-14 Superkine WO2018112219A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/442,265 US11053299B2 (en) 2010-09-21 2019-06-14 Superkine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434389P 2016-12-14 2016-12-14
US62/434,389 2016-12-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/238,925 Continuation-In-Part US8507222B2 (en) 2010-09-21 2011-09-21 Multimeric IL-15 soluble fusion molecules and methods of making and using same
US16/442,265 Continuation-In-Part US11053299B2 (en) 2010-09-21 2019-06-14 Superkine

Publications (2)

Publication Number Publication Date
WO2018112219A1 WO2018112219A1 (fr) 2018-06-21
WO2018112219A4 true WO2018112219A4 (fr) 2018-08-02

Family

ID=62559288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/066449 WO2018112219A1 (fr) 2010-09-21 2017-12-14 Superkine

Country Status (1)

Country Link
WO (1) WO2018112219A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388266B1 (fr) * 2007-05-11 2014-04-23 Altor BioScience Corporation Molécules de fusion et variantes de IL-15
AU2011305476B2 (en) * 2010-09-21 2016-12-01 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
ES2899890T3 (es) * 2014-06-30 2022-03-15 Altor Bioscience Corp Moléculas basadas en IL-15 y métodos de uso de las mismas

Also Published As

Publication number Publication date
WO2018112219A1 (fr) 2018-06-21

Similar Documents

Publication Publication Date Title
US20190177434A1 (en) Single-domain antigen-binding proteins that bind mammalian igg
US5767260A (en) Antigen-binding fusion proteins
JP7262597B2 (ja) 二重特異性抗体及びその作製方法と使用
US20070287170A1 (en) Engineered heterodimeric protein domains
US20160376304A1 (en) Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
TW201348247A (zh) 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
EP3635014B1 (fr) Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa
JPH09506001A (ja) 異種二重特異性抗体の製造法
CA3085446C (fr) Proteine dans laquelle une interaction electrostatique est introduite sur un site d'interaction hydrophobe et methode de preparation associee
SI2802606T1 (en) Improves the transfer of healing molecules through the hematoencephalic barrier
WO2017143840A1 (fr) Procédé d'expression et de préparation d'un anticorps polyvalent multi-spécifique et d'une protéine hybride immunitaire
WO2018090950A1 (fr) Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 de forme hétérodimère et sa préparation
EP2229409B1 (fr) Procédés destinés à accroître l'efficacité thérapeutique d'anticorps immunoglobulines g de classe 3 (igg3)
KR20120118013A (ko) Ｆｃ?함유 단백질을 정제하는 크로마토그래피 방법
JP2017534296A5 (fr)
CN111542536A (zh) 多特异性分子
CN111491951A (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
WO2019199916A1 (fr) Anticorps trispécifiques à base de fab
CN110590955B (zh) 一种双特异性抗体
Acheampong Bispecific antibody (bsAb) construct formats and their application in cancer therapy
JP2018502068A5 (fr)
WO2018112219A4 (fr) Superkine
Huang et al. Multispecific, Multivalent Antibody‐Based Molecules Engineered on the DART® and TRIDENTTM Platforms
Das et al. Comparative evaluation of two purification methods of anti-CD19-c-myc-His6-Cys scFv
JPH09124508A (ja) ヒト血漿の分別中に得られる画分から免疫グロブリンを回収する方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17880417

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17880417

Country of ref document: EP

Kind code of ref document: A1